The Gilead Sciences Inc.'s drug Ranexa has been found to reduce incidents of chest pain in patients suffering from diabetes.
In a drug trial conducted in 104 centers in 14 countries, researchers found that patients who took Ranexa (known chemically as ranolazine and already approved to treat the heart disease-caused chest pain known as angina) reported 3.8 weekly episodes of chest pain on average, compared to 4.3 episodes weekly reported by patients in the placebo group.
Lead researcher Dr. Mikhail Kosiborod, MD, from St. Luke's Mid America Heart Institute and University of Missouri, Kansas City said: "Ranolazine is an effective anti-anginal drug in patients with diabetes and may also have a glucose lowering effect. If the glucose lowering action of ranolazine is confirmed in future studies, patients with diabetes and angina may derive dual benefit from this drug."
The study results were presented at the American College of Cardiology (ACC) scientific meeting in San Francisco on Sunday.
For comments and feedback contact: editorial@rttnews.com
Health News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.